0.05Open0.05Pre Close41 Volume747 Open Interest1.00Strike Price159.00Turnover808.80%IV1.94%PremiumJul 19, 2024Expiry Date0.03Intrinsic Value100Multiplier-1DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.6568Delta4.3945Gamma20.60Leverage Ratio-0.4277Theta0.0000Rho13.53Eff Leverage0.0000Vega
Gossamer Bio Stock Discussion
loading...
loading...
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
• Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH).
• The firm has a $9 price target (~984% upside based on June 24 close).
• Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
No comment yet